MethylGene Reports Favorable Phase I Data For MGCD265 In Solid Tumors At The AACR-NCI-EORTC International Conference

MethylGene Inc. (TSX:MYG) reported preliminary Phase I data for MGCD265 in a poster session at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston.

Go to Source

People who read this also read

• New Use For Surgical Robot, Head And Neck Tumors
  On Dec. 16, the U.S. Food and Drug Administration cleared the da Vinci Surgical System® for benign and malignant tumors in such locations as the tongue, tonsils, mouth and voice box. Studies have found that, compared with conventional surgical techniques, the robotic system can result in shorter ho...
• Genetic Disease Known For Its Life-threatening Tumors Can Also Cause Sudden Death From Cardiovascular Disease In Children, Trial To Develop Treatments
  Researchers have discovered how a genetic disease known mainly for its life-threatening tumors also can cause sudden death from cardiovascular disease in children, and are mounting a clinical trial to develop treatments for the problem. Scientists from the Indiana University School of Medicine found...
• Study Documents Increasing Racial Disparities In Access To High Quality Care For Brain Tumors
  African Americans and Hispanic patients appear less likely than white patients to have access to high-quality surgical care for brain tumors, according to a report in the March issue of Archives of Surgery, one of the JAMA/Archives journals. The article is one of several in the issue focusing on ...
• Minority, Underprivileged Patients Not As Likely To Be Referred To Specialty Hospitals For Brain Tumors
  African-American, Hispanic, and economically disadvantaged patients with brain tumors are significantly less likely to be referred to high-volume hospitals that specialize in neurosurgery than other patients of similar age, the same gender, and with similar comorbidities, according to new research b...
• AngioScore Announces Favorable Results From The MASCOT Trial
  AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt® PTA Scoring Balloon Catheter for the treatment of femoro-popliteal P...